Press Releases
Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President
The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]
Global Alzheimer’s Platform Foundation (GAP) Supports New Bill from U.S. Representative Vern Buchanan
WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as […]
Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results
WASHINGTON, DC, Sept. 28, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s disease, marking an enormous milestone for millions of people living with Alzheimer’s disease. The positive trial results, released by Eisai Tuesday night, show that the novel drug helped slow cognitive decline […]
South Texas Health Clinic Applauded for Advancing Diverse Representation in Alzheimer’s Clinical Trials, Surmounting Challenges
GAP-Net Site El Faro Health and Therapeutics in Texas’ Starr County continues working to connect the area’s predominantly Hispanic community with access to Alzheimer’s research and health care. Washington, D.C. — Today, Global Alzheimer’s Platform Foundation (GAP) John Dwyer applauded the work that Dr. James Falcon and the whole El Faro Health and Therapeutics team […]
GAP President John Dwyer’s Statement to the Media on Lesné Research
There was justifiable ink given last month in the media to the Lesné research misconduct. But it missed the mark. The real Alzheimer’s story is the “amyloid hypothesis” related to A?*56 is a small fraction of the research being done in an industry that is funding, backed by a lot of heart, to find a […]
Global Alzheimer’s Platform Foundation and WCG Collaborate to Improve Access to Clinical Trials for Traditionally Underrepresented Communities
The new program will provide much-needed resources and workforce development opportunities for clinical trial sites challenged by a shortage of approved raters. WASHINGTON, DC, Aug.1 — The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational resources and training to support Alzheimer’s disease research. This will provide […]
More Volunteers from Traditionally Underrepresented Communities Needed in Alzheimer’s Clinical Trials
Global Alzheimer’s Platform Foundation to present information about trial diversity at the Alzheimer’s Association International Conference. WASHINGTON, DC, July 27, 2022 — As a leading organization focused on increasing participant diversity in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation® (GAP) will present data at the Alzheimer’s Association International Conference® 2022 (AAIC®) to share information about its […]
GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access
Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer’s Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six […]
GNS and the Global Alzheimer’s Platform Foundation® Partner to Advance Alzheimer’s R&D
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease Somerville, Mass., June 1st, 2022 — GNS, the leader in the use of “Virtual Patients,” Causal AI and simulation technology for biopharmaceutical drug discovery and development, and the Global Alzheimer’s Platform Foundation® (GAP) today […]
STATEMENT: THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® PRESIDENT JOHN DWYER CONDEMNS THE CMS DECISION TO LIMIT A CLASS OF ALZHEIMER’S DRUGS AS “RATIONING CARE”
Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage. CMS continues to treat all Alzheimer’s patients differently than any other class […]